A Comprehensive Review on Hepatic Encephalopathy: Pathophysiology, Symptoms, Epidemiology, Classification, Diagnosis and Treatment

Sandip Tejpal; Saajan Kumar Sharma; Astha Sharma; Sachit Sharma

doi:10.55544/jrasb.3.3.27

Authors

Sandip Tejpal Department of Pharmaceutical Sciences, Guru Nanak Dev University, Grand Trunk Road, Off NH 1, Amritsar-143005, Punjab, INDIA.
Saajan Kumar Sharma Department of Pharmaceutical Sciences, Guru Nanak Dev University, Grand Trunk Road, Off NH 1, Amritsar-143005, Punjab, INDIA.
Astha Sharma Department of Pharmaceutical Sciences, Guru Nanak Dev University, Grand Trunk Road, Off NH 1, Amritsar-143005, Punjab, INDIA.
Sachit Sharma Department of Pharmaceutical Sciences, Guru Nanak Dev University, Grand Trunk Road, Off NH 1, Amritsar-143005, Punjab, INDIA.

DOI:

https://doi.org/10.55544/jrasb.3.3.27

Keywords:

Hepatic encephalopathy, Pathophysiology, Diagnosis, Treatment

Abstract

The condition known as hepatic encephalopathy (HE) is a state of impaired brain function that can be reversed and is experienced by patients who are suffering from severe liver diseases. Neurotoxins, decreased neurotransmission as a result of metabolic anomalies in liver failure, changes in brain energy metabolism, systemic inflammatory response, and alterations of the blood brain barrier are the primary hypotheses that are still being explored in relation to the precise pathophysiology of hepatic encephalopathy (HE). There is a wide spectrum of severity regarding the neurological and mental symptoms that can be brought on by HE. For the purpose of diagnosing limited HE, abnormal psychometric tests are utilised. Alterations in personality, altered states of consciousness, gradual spatial and temporal disorientation, lethargy, stupor, and coma are some of the characteristics of HE that are clinically noticeable. For the purpose of diagnosis, specific testing is not required outside of clinical studies. HE is classified according to the underlying disease, the severity of symptoms, the length of time it has been present, and whether or not there are triggers that cause it to occur. Hepatic encephalopathy refers to a collection of neuropsychiatric illnesses that can be treated and are characterised by the presence of symptoms in individuals who have liver disease or who have undergone portosystemic shunting. Entephalopathy, a disabling result of cirrhosis, affects thirty-five percent to forty-five percent of cirrhotic patients. Before recently, the treatment choices for HE that were available in hospitals were depending on anecdotal evidence, the availability of medication, and the norms of the relevant institutions. An increasing number of randomised controlled trials (RCTs) are providing further confirmation of the central significance of the basic HE therapy techniques (lactulose, branched-chain amino acids, and rifaximin), as well as the rising body of evidence showing the large beneficial advantages associated with these strategies. The liver transplantation and embolisation of large PSSs are two treatments that have proven to be effective for a select group of patients who have been carefully selected. Not only does it have a significant influence on the day-to-day lives of patients and carers, but it is also associated with increased rates of sickness and death and consumes a significant amount of resources in the healthcare system. In this article, we examine the history of hepatic encephalopathy, as well as the current understanding of the condition and the potential treatments for it.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Kaplan, P. W., & Rossetti, A. O. (2011). EEG patterns and imaging correlations in encephalopathy: encephalopathy part II. Journal of Clinical Neurophysiology, 28(3), 233-251.

D'amico, G., Morabito, A., Pagliaro, L., Marubini, E., & Liver Study Group of “V. Cervello” Hospital. (1986). Survival and prognostic indicators in compensated and decompensated cirrhosis. Digestive diseases and sciences, 31, 468-475.

Ito, T., Ikeda, N., Watanabe, A., Sue, K., Kakio, T., Mimura, H., & Tsuji, T. (1992). Obliteration of portal systemic shunts as therapy for hepatic encephalopathy in patients with non-cirrhotic portal hypertension. Gastroenterologia Japonica, 27, 759-764.

Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., ... & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 60(2), 715-735.

Bai, M., Qi, X., Yang, Z., Yin, Z., Nie, Y., Yuan, S., ... & Fan, D. (2011). Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review. Journal of gastroenterology and hepatology, 26(6), 943-951.

Riggio, O., Efrati, C., Catalano, C., Pediconi, F., Mecarelli, O., Accornero, N., ... & Merli, M. (2005). High prevalence of spontaneous portal‐systemic shunts in persistent hepatic encephalopathy: a case‐control study. Hepatology, 42(5), 1158-1165.

Simón-Talero, M., Roccarina, D., Martínez, J., Lampichler, K., Baiges, A., Low, G., ... & Botella, E. R. (2018). Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology, 154(6), 1694-1705.

Porcheron, J., & Balique, J. G. (1995, October). Physiopathology and surgical treatment of hepatic encephalopathy after porto-caval anastomosis. In Annales de Gastroenterologie et D'hepatologie (Vol. 31, No. 5, pp. 287-294).

Ridola, L., Cardinale, V., & Riggio, O. (2018). The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. Annals of Gastroenterology, 31(2), 151.

Nardelli, S., Gioia, S., Faccioli, J., Riggio, O., & Ridola, L. (2019). Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy. World Journal of Gastroenterology, 25(35), 5257.

Bustamante, J., Rimola, A., Ventura, P. J., Navasa, M., Cirera, I., Reggiardo, V., & Rodés, J. (1999). Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of hepatology, 30(5), 890-895.

Montagnese, S., Russo, F. P., Amodio, P., Burra, P., Gasbarrini, A., Loguercio, C., ... & Scarpignato, C. (2019). Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and liver disease, 51(2), 190-205.

Patidar, K. R., & Bajaj, J. S. (2015). Covert and overt hepatic encephalopathy: diagnosis and management. Clinical Gastroenterology and Hepatology, 13(12), 2048-2061.

Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., ... & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 60(2), 715-735.

Gerber, T., & Schomerus, H. (2000). Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs, 60, 1353-1370.

Poordad, F. F. (2007). The burden of hepatic encephalopathy. Alimentary pharmacology & therapeutics, 25, 3-9.

Bustamante, J., Rimola, A., Ventura, P. J., Navasa, M., Cirera, I., Reggiardo, V., & Rodés, J. (1999). Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of hepatology, 30(5), 890-895.

Wong, R. J., Gish, R. G., & Ahmed, A. (2014). Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transplantation, 20(12), 1454-1461.

Tapper, E. B., Jiang, Z. G., & Patwardhan, V. R. (2015, May). Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. In Mayo Clinic Proceedings (Vol. 90, No. 5, pp. 646-658). Elsevier.

Romero-Gómez, M., Jover, M., Del Campo, J. A., Royo, J. L., Hoyas, E., Galán, J. J., ... & Ruiz, A. (2010). Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Annals of internal medicine, 153(5), 281-288.

Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., ... & Gillevet, P. M. (2014). Altered profile of human gut microbiome is associated with cirrhosis and its complications. Journal of hepatology, 60(5), 940-947.

Shawcross, D., & Jalan, R. (2005). The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cellular and Molecular Life Sciences CMLS, 62, 2295-2304.

Liu, Q., Duan, Z. P., Ha, D. K., Bengmark, S., Kurtovic, J., & Riordan, S. M. (2004). Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology, 39(5), 1441-1449.

Dam, G., Vilstrup, H., Watson, H., & Jepsen, P. (2016). Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology, 64(4), 1265-1272.

Goldbecker, A., Weissenborn, K., Shahrezaei, G. H., Afshar, K., Rümke, S., Barg-Hock, H., ... & Tryc, A. B. (2013). Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut, 62(10), 1497-1504.

Hawkins, R. A., Jessy, J., Mans, A. M., Chedid, A., & DeJoseph, M. R. (1994). Neomycin reduces the intestinal production of ammonia from glutamine. Hepatic Encephalopathy, Hyperammonemia, and Ammonia Toxicity, 125-134.

Sharma, K., Akre, S., Chakole, S., & Wanjari, M. B. (2022). Hepatic Encephalopathy and Treatment Modalities: A Review Article. Cureus, 14(8), e28016. https://doi.org/10.7759/cureus.28016

Tapper, E. B., Parikh, N. D., Sengupta, N., Mellinger, J., Ratz, D., Lok, A. S. F., & Su, G. L. (2018). A risk score to predict the development of hepatic encephalopathy in a population‐based cohort of patients with cirrhosis. Hepatology, 68(4), 1498-1507.

Orman, E. S., Roberts, A., Ghabril, M., Nephew, L., Desai, A. P., Patidar, K., & Chalasani, N. (2019). Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis. JAMA network open, 2(6), e196412-e196412.

Potnis, A., VanMeter, S., & Stange, J. (2021). Prevalence of hepatic encephalopathy from a commercial medical claims database in the United States. International Journal of Hepatology, 2021(1), 8542179.

American Association for the Study of Liver Diseases. (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of hepatology, 61(3), 642-59.

Amodio, P. (2015). Hepatic encephalopathy: historical remarks. Journal of Clinical and Experimental Hepatology, 5, S4-S6.

Parsons-Smith, B. G., Summerskill, W. H. J., Dawson, A. M., & Sherlock, S. (1957). The electroencephalograph in liver disease. The Lancet, 270(7001), 867-871.

Rikkers, L., Jenko, P., Rudman, D., & Freides, D. (1978). Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology, 75(3), 462-469.

Ferenci, P., Lockwood, A., Mullen, K., Tarter, R., Weissenborn, K., & Blei, A. T. (2002). Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology, 35(3), 716-721.

Córdoba, J. (2011). New assessment of hepatic encephalopathy. Journal of hepatology, 54(5), 1030-1040.

Bajaj, J. S., Cordoba, J., Mullen, K. D., Amodio, P., Shawcross, D. L., Butterworth, R. F., & Morgan, M. Y. (2011). the design of clinical trials in hepatic encephalopathy–an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary pharmacology & therapeutics, 33(7), 739-747.

Hassanein, T. I., Hilsabeck, R. C., & Perry, W. (2008). Introduction to the hepatic encephalopathy scoring algorithm (HESA). Digestive diseases and sciences, 53, 529-538.

Hassanein, T., Blei, A. T., Perry, W., Hilsabeck, R., Stange, J., Larsen, F. S., ... & Fontana, R. (2009). Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Official journal of the American College of Gastroenterology| ACG, 104(6), 1392-1400.

Ortiz, M., Cordoba, J., Doval, E., Jacas, C., Pujadas, F., Esteban, R., & Guardia, J. (2007). Development of a clinical hepatic encephalopathy staging scale. Alimentary pharmacology & therapeutics, 26(6), 859-867.

Bajaj, J. S., Wade, J. B., & Sanyal, A. J. (2009). Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology, 50(6), 2014-2021.

Montagnese, S., Balistreri, E., Schiff, S., De Rui, M., Angeli, P., Zanus, G., ... & Amodio, P. (2014). Covert hepatic encephalopathy: agreement and predictive validity of different indices. World journal of gastroenterology: WJG, 20(42), 15756.

Thomsen, K. L., Macnaughtan, J., Tritto, G., Mookerjee, R. P., & Jalan, R. (2016). Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PloS one, 11(1), e0146076.

Montagnese, S., De Rui, M., Angeli, P., & Amodio, P. (2017). Neuropsychiatric performance in patients with cirrhosis: Who is "normal"?. Journal of hepatology, 66(4), 825–835. https://doi.org/10.1016/j.jhep.2016.11.021

American Association for the Study of Liver Diseases. (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of hepatology, 61(3), 642-59.

Guerit, J. M., Amantini, A., Fischer, C., Kaplan, P. W., Mecarelli, O., Schnitzler, A., ... & members of the ISHEN commission on Neurophysiological Investigations. (2009). Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver International, 29(6), 789-796.

Randolph, C., Hilsabeck, R., Kato, A., Kharbanda, P., Li, Y. Y., Mapelli, D., ... & Weissenborn, K. (2009). Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver international, 29(5), 629-635.

Prakash, R. K., Brown, T. A., & Mullen, K. D. (2011). Minimal hepatic encephalopathy and driving: is the genie out of the bottle?. Official journal of the American College of Gastroenterology| ACG, 106(8), 1415-1416.

Lockwood, A. H. (2004). Blood ammonia levels and hepatic encephalopathy. Metabolic brain disease, 19, 345-349.

Sharma, K., Akre, S., Chakole, S., & Wanjari, M. B. (2022). Hepatic Encephalopathy and Treatment Modalities: A Review Article. Cureus, 14(8), e28016. https://doi.org/10.7759/cureus.28016

Ferenci, P., Herneth, A., & Steindl, P. (1996). Newer approaches to therapy of hepatic encephalopathy. In Seminars in liver disease (Vol. 16, No. 03, pp. 329-338). © 1996 by Thieme Medical Publishers, Inc..

Conn, H. O., Leevy, C. M., Vlahcevic, Z. R., Rodgers, J. B., Maddrey, W. C., Seeff, L., & Levy, L. L. (1977). Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind controlled trial. Gastroenterology, 72(4), 573-583.

Sharma, P., & Sarin, S. K. (2012). Disaccharides in the treatment of hepatic encephalopathy. Hepatic Encephalopathy, 141-158.

Miglio, F., Valpiani, D., Ricca Rossellini, S., Ferrieri, A., & Canova, N. (1997). Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Current medical research and opinion, 13(10), 593-601.

Strauss, E., Tramote, R., Silva, E. P., Caly, W. R., Honain, N. Z., Maffei, R. A., & de Sá, M. F. (1992). Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepato-gastroenterology, 39(6), 542-545.

Korean Association for the Study of the Liver (KASL. (2020). KASL clinical practice guidelines for liver cirrhosis: varices, hepatic encephalopathy, and related complications. Clinical and molecular hepatology, 26(2), 83.

Martin, P., DiMartini, A., Feng, S., Brown Jr, R., & Fallon, M. (2014). Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology, 59(3), 1144-1165.

Ferenci P. (2017). Hepatic encephalopathy. Gastroenterology report, 5(2), 138–147. https://doi.org/10.1093/gastro/gox013

Green, E. W., & Mitra, A. (2022). Diagnosis and management of hepatic encephalopathy: A summary for patients. Clinical liver disease, 20(3), 90–92. https://doi.org/10.1002/cld.1236

Ridola, L., Faccioli, J., Nardelli, S., Gioia, S., & Riggio, O. (2020). Hepatic Encephalopathy: Diagnosis and Management. Journal of translational internal medicine, 8(4), 210–219. https://doi.org/10.2478/jtim-2020-0034

Riggio, O., Ridola, L., & Pasquale, C. (2010). Hepatic encephalopathy therapy: An overview. World journal of gastrointestinal pharmacology and therapeutics, 1(2), 54–63. https://doi.org/10.4292/wjgpt.v1.i2.54

Hoilat, G. J., Suhail, F. K., Adhami, T., & John, S. (2022). Evidence-based approach to management of hepatic encephalopathy in adults. World journal of hepatology, 14(4), 670–681. https://doi.org/10.4254/wjh.v14.i4.670

Elwir, S., & Rahimi, R. S. (2017). Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. Journal of clinical and translational hepatology, 5(2), 142–151. https://doi.org/10.14218/JCTH.2016.00069

Poh, Z., & Chang, P. E. (2012). A current review of the diagnostic and treatment strategies of hepatic encephalopathy. International journal of hepatology, 2012, 480309. https://doi.org/10.1155/2012/480309

Chela, H. K., Basra, N., & Naqvi, S. H. (2019). Hepatic Encephalopathy in the Hospitalized Patient: A Review for Hospitalists. Missouri medicine, 116(4), 308–312.